Zhu J et al. identified the atypical E3 ubiquitin ligase RNF31 as a potential therapeutic target for BC patients, as it is highly expressed in BC and stabilizes estrogen receptor α (ER α) while participating in p53 degradation [9,10]. Here, TP53 is linked to breast cancer.